

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

NOVO NORDISK A/S,
Patent Owner

Case IPR2023-00724
Patent 10,335,462

DECLARATION OF DEVRAJ CHAKRAVARTY

I, Devraj Chakravarty, hereby declare under penalty of perjury:

1. I am an Associate Director, Regulatory Affairs at Novo Nordisk Inc.¹

Except as otherwise indicated, I have personal knowledge of the facts set forth in this Declaration. All statements herein made of my own knowledge are true and all statements made on information and belief are believed to be true. If called upon to do so, I would testify competently thereto.

2. EX2048 is a true and correct copy of a document titled Drug Product Semaglutide B, 1.34 mg/ml, Description and Composition of the Drug Product, dated June 6, 2014. This document accurately reflects the formulation (which we refer to as “Semaglutide B”) that was used in the clinical trials for SUSTAIN 6 and FLOW trials for the 1.0 mg dosage. This is the same formulation used for Novo Nordisk’s commercial product Ozempic®. This document was stored in Novo Nordisk’s regulatory files. This document was made and kept in the regular and ordinary course of Novo Nordisk’s business, at or near the date appearing on the

¹ Novo Nordisk Inc. is a privately held corporation wholly owned by Novo Nordisk Commercial Holdings, Inc. Novo Nordisk Commercial Holdings, Inc. is wholly owned by Novo Nordisk US Holdings Inc. Novo Nordisk US Holdings Inc. is a privately held corporation wholly owned by Novo Nordisk A/S.

document (June 6, 2014), and was made by persons with knowledge of the facts and opinions stated therein.

I have been warned that willful false statements and the like are punishable by fine or imprisonment, or both (18 U.S.C. 1001) and may jeopardize the validity of the patent at issue in this proceeding. I declare under penalty of perjury that the foregoing is true and correct.

Executed on January 17, 2024 at Plainsboro, New Jersey.

/Devraj Chakravarty/

Devraj Chakravarty